For example, the RELATIVITY-047 trial evaluating nivolumab plus the LAG-3 inhibitor relatlimab has shown promise in melanoma, and similar combinations are now being explored in HNSCC [12,121]. Here, LAG3 is linked to head and neck squamous cell carcinoma.